{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cardenas G"],"funding":["dgapa-unam, papiit","mexican agency for international development cooperation"],"pagination":["148"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8845269"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(1)"],"pubmed_abstract":["<h4>Background</h4>By end December of 2021, COVID-19 has infected around 276 million individuals and caused over 5 million deaths worldwide. Infection results in dysregulated systemic inflammation, multi-organ dysfunction, and critical illness. Cells of the central nervous system are also affected, triggering an uncontrolled neuroinflammatory response. Low doses of glucocorticoids, administered orally or intravenously, reduce mortality among moderate and severe COVID-19 patients. However, low doses administered by these routes do not reach therapeutic levels in the CNS. In contrast, intranasally administered dexamethasone can result in therapeutic doses in the CNS even at low doses.<h4>Methods</h4>This is an approved open-label, multicenter, randomized controlled trial to compare the effec"],"journal":["Trials"],"pubmed_title":["Intranasal dexamethasone: a new clinical trial for the control of inflammation and neuroinflammation in COVID-19 patients."],"pmcid":["PMC8845269"],"funding_grant_id":["318.01","IN201020"],"pubmed_authors":["Murillo MFM","Araujo LVT","Martinez-Cuazitl A","Hernandez PS","Hernandez-Aceves JA","Meneses G","Laclette JP","Huerta L","Moncivais AS","Del Rio Ambriz LR","Malagon DA","Leon-Hernandez M","Chavez-Canales M","Perez-Tapia M","Bobes RJ","Romano MC","Lopez-Alvarenga J","Besedovsky H","Rosas G","Espindola-Arriaga E","Cervantes-Torres J","Salazar INM","Bonilla RAA","Espinosa AM","Leyva Y","Pena AF","Velazquez EG","Reynoso RIA","Soldevila G","Alor RO","Cresencio KI","Reyes DM","Rodriguez AF","Cardenas G","Mendoza SR","de la Cerda MR","Sciutto E","Cruz J","Fierro NA","Wong-Chew RM","Chinney A","Gonzalez LER","Campos RLB","Jung H","Salazar EA","Hernandez M","Sarmiento EB","Fragoso G","Quero KM","Francisco SO","Diaz SH","Martinez IRZ","Jordan-Rios A","Hernandez-Ruiz J","Hernandez-Medel ML"],"additional_accession":[]},"is_claimable":false,"name":"Intranasal dexamethasone: a new clinical trial for the control of inflammation and neuroinflammation in COVID-19 patients.","description":"<h4>Background</h4>By end December of 2021, COVID-19 has infected around 276 million individuals and caused over 5 million deaths worldwide. Infection results in dysregulated systemic inflammation, multi-organ dysfunction, and critical illness. Cells of the central nervous system are also affected, triggering an uncontrolled neuroinflammatory response. Low doses of glucocorticoids, administered orally or intravenously, reduce mortality among moderate and severe COVID-19 patients. However, low doses administered by these routes do not reach therapeutic levels in the CNS. In contrast, intranasally administered dexamethasone can result in therapeutic doses in the CNS even at low doses.<h4>Methods</h4>This is an approved open-label, multicenter, randomized controlled trial to compare the effec","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2025-04-19T13:45:00.87Z","creation":"2024-12-04T03:38:39.199Z"},"accession":"S-EPMC8845269","cross_references":{"pubmed":["35164840"],"doi":["10.1186/s13063-022-06075-5"]}}